In addition, studies have shown that exosome derived DNA mutations (such as KRAS and TP53) can also be selected in the diagnosis of pancreatic cancer, and the diagnostic efficiency is better than CTC, but exosome KRAS mutations can also occur in healthy people (29). This evidence concerns the gene TP53 and familial pancreatic carcinoma.